野村发表报告指，维持先前药明合联(02268.HK) 2024和2025财年预测，意味预期公司2024财年下半年营收与纯利按年增长分别为54%和255%。预测公司2025财年销售额按年增长50%，高于管理阶层在1月提出的35%指引。
野村对该股目标价由34.11元升至42.5元。维持“买入”评级。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-19 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.